https://www.selleckchem.com/pr....oducts/relacorilant.
034] and anti-metabolite-based immunosuppression protocols (89% vs. 44%, P= 0.011) were associated with low immunogenicity. Importantly, 36% of HTx recipients who were non-responders to the first vaccine dose became S-IgG seropositive in response to the second vaccine dose. Approximately a half of HTx recipients did not generate S-IgG antibodies following SARS-CoV-2 two-dose vaccine. The generally achieved protection from SARS-CoV-2 mRNA vaccination should be regarded with caution in the population of HTx recipients. The possible b
Like
Comment
Share
